Human CD27 Ligand/TNFSF7 Antibody Summary
Gln45-Pro193
Accession # AAA36175
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of CD27Ligand/TNFSF7 in HEK293 Human Cell Line Transfected with Human CD27 Ligand/TNFSF7 by Flow Cytometry. HEK293 human embryonic kidney cell line transfected with human CD27 Ligand/TNFSF7 (filled histogram) or irrelevant protein (open histogram) was stained with Mouse Anti-Human CD27 Ligand/TNFSF7 Monoclonal Antibody (Catalog # MAB2738) followed by Goat anti-mouse PE-conjugated secondary antibody (F0102B). Staining was performed using our Staining Membrane-associated Proteins protocol.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD27 Ligand/TNFSF7
CD27 Ligand is a member of the tumor necrosis factor superfamily (TNFSF7) and is also designated CD70. CD27 Ligand is a type II transmembrane protein expressed by activated T and B cells. It binds to CD27 on mature T cells and a subset of thymocytes. CD27 Ligand induces the proliferation of costimulated T cells and enhances the generation of cytolytic T cells.
Product Datasheets
Citations for Human CD27 Ligand/TNFSF7 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
10
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
CD70 antibody‐drug conjugate: A potential novel therapeutic agent for ovarian cancer
Authors: Mayu Shiomi, Shinya Matsuzaki, Satoshi Serada, Koji Matsuo, Chihiro Mizuta‐Odani, Mariko Jitsumori et al.
Cancer Science
-
HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma
Authors: Miikkulainen P, Hogel H, Rantanen K et al.
Cancer Metab
-
Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma
Authors: David S. Tourigny, Mark Zucker, Minsoo Kim, Paul Russo, Jonathan Coleman, Chung-Han Lee et al.
Frontiers in Oncology
-
CD28 costimulation augments CAR signaling in NK cells via the LCK/CD3Z/ZAP70 signaling axis
Authors: Acharya, S;Basar, R;Daher, M;Rafei, H;Li, P;Uprety, N;Ensley, E;Shanley, M;Kumar, B;Banerjee, PP;Melo Garcia, L;Lin, P;Mohanty, V;Kim, KH;Jiang, X;Pan, Y;Li, Y;Liu, B;Nunez Cortes, AK;Zhang, C;Fathi, M;Rezvan, A;Montalvo, MJ;Cha, SL;Reyes-Silva, F;Shrestha, R;Guo, X;Kundu, K;Biederstadt, A;Muniz-Feliciano, L;Deyter, GM;Kaplan, M;Jiang, XR;Liu, E;Jain, A;Roszik, J;Fowlkes, NW;Solis Soto, LM;Raso, MG;Khoury, JD;Lin, P;Vega, F;Varadarajan, N;Chen, K;Marin, D;Shpall, EJ;Rezvani, K;
Cancer discovery
Species: Human
Sample Types: Whole Tissue
Applications: Immunohistochemistry -
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts
Authors: Van den Eynde, A;Gehrcken, L;Verhezen, T;Lau, HW;Hermans, C;Lambrechts, H;Flieswasser, T;Quatannens, D;Roex, G;Zwaenepoel, K;Marcq, E;Joye, P;Cardenas De La Hoz, E;Deben, C;Gasparini, A;Montay-Gruel, P;Le Compte, M;Lion, E;Lardon, F;Van Laere, S;Siozopoulou, V;Campillo-Davo, D;De Waele, J;Pauwels, P;Jacobs, J;Smits, E;Van Audenaerde, JRM;
Journal of hematology & oncology
Species: Human
Sample Types: Whole Tissue
Applications: Immunohistochemistry -
CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma
Authors: Huang, RR;Chen, Z;Kroeger, N;Pantuck, A;Said, J;Kluger, HM;Shuch, B;Ye, H;
Clinical genitourinary cancer
Species: Human
Sample Types: Whole Tissue
-
CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma
Authors: R Nakae, S Matsuzaki, S Serada, K Matsuo, M Shiomi, K Sato, Y Nagase, S Matsuzaki, S Nakagawa, K Hiramatsu, A Okazawa, T Kimura, T Egawa-Taka, E Kobayashi, Y Ueda, K Yoshino, T Naka, T Kimura
Am. J. Obstet. Gynecol., 2020-08-19;0(0):.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method
Authors: T Flieswasse, V Camara-Cla, A Danu, J Bosq, V Ribrag, P Zabrocki, L Van Rompae, H de Haard, K Zwaenepoel, E Smits, P Pauwels, J Jacobs
Cancers (Basel), 2019-10-22;11(10):.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma
Authors: UB Hagemann, D Mihaylova, SR Uran, J Borrebaek, D Grant, RM Bjerke, J Karlsson, AS Cuthbertso
Oncotarget, 2017-01-01;0(0):.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC -
The dual role of CD70 in B‐cell lymphomagenesis
Authors: Man Nie, Weicheng Ren, Xiaofei Ye, Mattias Berglund, Xianhuo Wang, Karin Fjordén et al.
Clinical and Translational Medicine
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CD27 Ligand/TNFSF7 Antibody
Average Rating: 4 (Based on 1 Review)
Have you used Human CD27 Ligand/TNFSF7 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
